Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Gary Richmond

Pulmonary Disease Fort Lauderdale, FL Medical Doctor

NPI 1255345963 CMS profile 56914

812 Sw 12Th Ave, Broward Health Medical Center, Fort Lauderdale, FL 33312

Open in the dashboard

General payments

$12,018

92 records reported · program years 2019–2023

Research payments

$218,523

Paid to them · 39 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,105,932 paid to institutions, not to them · program years 2019–2024

Through program year 2023, Gary Richmond of Fort Lauderdale, FL is reported in the CMS Open Payments database as having received $12,018 across 92 general payments and $218,523 in research payments paid to them. Separately, studies naming them as principal investigator received $2,105,932 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $125 1
2023 Research $1,972 2
2022 General $2,637 5
2022 Research $214,916 20
2021 General $1,500 33
2020 General $731 20
2019 General $7,025 33
2019 Research $1,635 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Richmond
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Gary Richmond were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Gary Richmond Pulmonary Disease median Middle half National median
2019 $7,025 $377 $109–$1,340 $163
2020 $731 $230 $56–$907 $114
2021 $1,500 $269 $68–$1,072 $132
2022 $2,637 $390 $100–$1,457 $149
2023 $125 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Insmed, Inc. $6,722 14 payments
  2. Theratechnologies Inc. $2,500 1 payment
  3. Gilead Sciences, Inc. $1,329 13 payments
  4. ViiV Healthcare Company $427 26 payments
  5. Janssen Products, LP $287 3 payments
  6. GlaxoSmithKline, LLC. $182 9 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $125 1 payment
  8. Actelion Pharmaceuticals US, Inc. $98 2 payments
  9. United Therapeutics Corporation $65 6 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $64 3 payments
  11. Other $219 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Consulting Fee $8,560 5 payments
  2. Food and Beverage $1,927 75 payments
  3. Travel and Lodging $1,061 4 payments
  4. Education $470 8 payments
Products named General payments · program years 2019–2023
  1. Arikayce $6,589 13 payments
  2. SYMTUZA $313 4 payments
  3. DOVATO $277 24 payments
  4. Biktarvy $246 2 payments
  5. CABENUVA $150 2 payments
  6. Adempas $125 1 payment
  7. TRELEGY ELLIPTA $114 2 payments
  8. OPSUMIT $98 2 payments
  9. UPTRAVI $77 1 payment
  10. TYVASO $44 2 payments
  11. Other $330 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Theratechnologies Inc. $216,888 22 payments
  2. Gilead Sciences, Inc. $1,635 17 payments

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record